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ABSTRACT
Activation of the neuronal–glial network in the spinal cord
dorsal horn (SCDH) mediates various chronic painful condi-
tions. We studied spinal neuronal–astrocyte signaling inter-
actions involved in the maintenance of painful diabetic neu-
ropathy (PDN) in type 2 diabetes. We used the db/db
mouse, an animal model for PDN of type 2 diabetes, which
develops mechanical allodynia from 6 to 12 wk of age. In
this study, enhanced substance P expression was detected
in the presynaptic sensory fibers innervating lamina I–III
in the lumbar SCDH (LSCDH) of the db/db mouse at 10 wk
of age. This phenomenon is associated with enhanced spinal
ERK1/2 phosphorylation in projection sensory neurons and
regional astrocyte activation. In addition, peak phosphoryl-
ation of the NR1 subunit of N-methyl-D-aspartate receptor
(NMDAR), along with upregulation of neuronal and induci-
ble nitric oxide synthase (nNOS and iNOS) expression were
detected in diabetic mice. Expression of nNOS and iNOS
was detected in both interneurons and astrocytes in lamina
I–III of the LSCDH. Treatment with MK801, an NMDAR
inhibitor, inhibited mechanical allodynia, ERK1/2 phospho-
rylation, and nNOS and iNOS upregulation in diabetic
mice. MK801 also reduced astrocytosis and glial acidic
fibrillary protein upregulation in db/db mice. In addition,
N(G)-nitro-L-arginine methyl ester (L-NAME), a nonspecific
NOS inhibitor, had similar effects on NMDAR signaling
and NOS expression. These results suggest that nitric oxide
from surrounding interneurons and astrocytes interacts
with NMDAR-dependent signaling in the projection neu-
rons of the SCDH during the maintenance of PDN. VC 2012
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INTRODUCTION
Diabetic neuropathy affects up to 50% of patients
with type 1 or type 2 diabetes (Boulton et al., 2005;
Feldman et al., 2005). Among these patients, approxi-
mately 30% develop painful diabetic neuropathy (PDN;
Davies et al., 2006). Although PDN is a common symp-
tom among diabetic patients, its mechanisms remain
unclear. PDN is more prevalent in type 2 than in type
1 diabetes (Barrett et al., 2007); however, most pub-
lished studies for PDN use animal models of type 1 di-
abetes. Understanding the mechanisms of PDN as it
develops in the context of type 2 diabetes could lead to
development of effective treatments to target the mech-
anisms behind this devastating disease. We have previ-
ously characterized the db/db mouse as a model for
PDN of type 2 diabetes (Cheng et al., 2009). The db/db
mouse carries a homozygous null mutation of the leptin
receptor (Hummel et al., 1966; Sullivan et al., 2007).
We reported that the db/db mouse develops features of
PDN, including mechanical allodynia at 6–12 wk of age
and evident sensory neuropathy at 24 wk of age
(Cheng et al., 2009; Sullivan et al., 2007). We reported
that the initiation of mechanical allodynia in db/db
mice is associated with early peripheral mechanisms,
including increased NGF/Trk A receptor signaling in
dorsal root ganglion (DRG) neurons before 8 wk of age.
In this study, we report that these initial peripheral
mechanisms activate the neuronal–glial interactions in
spinal cord dorsal horn (SCDH) to mediate chronic
PDN. Chronic pain is associated with enhanced spinal
cord neuronal activity known as central sensitization
(Latremoliere and Woolf, 2009). It is well known that
the neuronal N-methyl-D-aspartate receptor (NMDAR)
mediates central sensitization in SCDH. In addition, re-
gional microglial and astrocytic activation also contrib-
utes to chronic pain (Beggs and Salter, 2010; Gao and
Ji, 2010b). We demonstrated that increased peripheral
nociceptive signals could lead to central spinal cord
(SC) NMDAR-mediated neuron–astrocyte interactions.
We tested the activation of NMDAR and related down-
stream nociceptive events, including ERK1/2 activation
and enhanced nitric oxide synthase (NOS) levels in
neuron and astrocytes in the lumbar SCDH (LSCDH).
These signaling cascades are enhanced by nitric oxide
(NO). Our findings provide new understanding of the
molecular mechanisms of PDN of type 2 diabetes and
indicate that blocking NMDAR and NO signaling could
be effective treatments for PDN of type 2 diabetes.
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MATERIALS AND METHODS
Animals
Male C57BLKS db/db mice were purchased from Jack-
son Laboratories (Bar Harbor, Maine; stock number
000642). The homozygous (Leprdb/Leprdb or db/db) mice
were used as a model of type 2 diabetes, whereas hetero-
zygous mice (Leprdb/1 or db1) served as nondiabetic con-
trols. Analyses and procedures were performed in compli-
ance with protocols established by the Animal Models of
Diabetic Complications Consortium (http://www.amdc-
c.org) and were approved by the Use and Care of Animals
Committee at the University of Michigan.
Mechanical Allodynia
The animals were placed in a Plexiglass cage with
mesh flooring and allowed to acclimatize for 1 h. A loga-
rithmic series of calibrated monofilaments (Von Frey
hairs; Stoelting, Wood Dale, IL) were applied to the mid-
plantar surface of the hind paw and pressed to the point
of bending. Brisk withdrawal of the stimulated paw was
recorded as a positive response. Testing began with the
1 g filament followed by larger filaments, using the up–
down method (Dixon, 1980). Although all responses
were noted, counting of the critical six data points did
not begin until the response threshold was first crossed.
The resulting pattern of the six positive and negative
responses was tabulated, and the 50% gram threshold
was calculated using the formula described previously
(Chaplan et al., 1994).
Immunoblots
After deep anesthesia, L4-6 SC were dissected from
four mice per condition (db/db and db1) and homoge-
nized in ice-cold Tissue Protein Extraction Reagent, T-
PER (Pierce Biotechnology, Rockford, IL) containing pro-
tease inhibitors (1 lM sodium orthovanadate and 1 lM
sodium fluoride; Sigma Life Science, St. Louis, MO) and
phosphatase inhibitors (13; Thermo Scientific, Rockford,
IL). Fifty micrograms of protein was boiled in 23 sample
buffer, separated on a sodium dodecyl polyacrylamide
gel electrophoresis gel, and transferred to a polyvinyli-
dene fluoride membrane. Membranes were blocked and
incubated overnight at 4C with primary antibodies:
phospho-NR1 (pNR1, 1:1000, rabbit polyclonal; Milli-
pore, Temecula, CA), total NR1 (1:1000, rabbit polyclo-
nal; Millipore), phospho-extracellular signal-regulated
kinases (pERK1/2, 1:1000; Millipore), total ERK1/2
(1:1000; Millipore), phospho-c-jun N-terminal kinase
(pJNK, 1:1000; Millipore), total JNK (1:1000; Millipore),
neuronal NOS (nNOS) (1:1000; Abcam, Cambridge, MA),
inducible NOS (iNOS) (1:1000; Abcam), and glial acidic
fibrillary protein (GFAP, 1:1000; Abcam). Membranes
were then rinsed and incubated with horseradish peroxi-
dase–conjugated secondary antibodies for 1 h at 25C
and processed with chemiluminescence substrate (Pierce
Biotechnology) before being exposed to Hyperfilm (Amer-
sham, Piscataway, NJ). Densitometry was performed
using Image J software, and the results were normalized
against actin densities from the same sample.
Immunohistochemistry
Four mice from each group (db1 and db/db) were
deeply anesthetized and perfused with 2% paraformalde-
hyde in phosphate-buffered saline (PBS; pH 7.2, 0.1 M).
L4-6 SC were dissected, embedded in mounting media
(OCT), and flash frozen in liquid nitrogen. Tissue sec-
tions (15 lm) were cut, rehydrated with PBS, and
blocked in 0.1% TX-100 and 5% nonfat dry milk in PBS.
For pERK1/2 and nNOS immunohistochemistry (IHC),
sections were treated with hot citric acid (10 mM sodium
citrate and 0.05% Tween 20, pH 6.0) for 3 min followed
by rinsing with PBS. Sections were then incubated at
room temperature for 16–24 h with primary antibodies:
pERK1/2 (1:100), substance P (SP) (1:500, rat monoclo-
nal; Abcam), nNOS (1:200), iNOS (1:100), and GFAP
(1:1000; Abcam). Sections were then rinsed three times
in PBS and incubated with secondary antiserum conju-
gated with different fluorophores (Alexa Fluor 488, 594,
or 647; Invitrogen, Carlsbad, CA). Neurons were identi-
fied using NeuN antibody (1:250, Neuronal Nuclei, Alexa
Fluor 488; Millipore). Fluorescent signals were exam-
ined using an Olympus FluoView 500 laser scanning
confocal microscope. The percentage of immunopositive
cells was analyzed by counting the number of immuno-
positive neurons and multiplying by (100/total number
of neurons). A total of six lumbar spinal cord (LSC) sec-
tions from each animal were measured in a blinded
fashion. Sections were incubated with primary antisera
alone and secondary antisera alone to ensure specificity.
Inhibitor Treatments
Several reagents were used in the current study: an
NMDAR antagonist, (5S,10R)-(–)-5-methyl-10,11-dihy-
dro-5H-dibenzo[a,d]acyclohepten-5,10-imine hydrogen
maleate (MK801, 0.25 mg/kg, Sigma), or saline control
were administered intraperitoneally. N-nitro-L-arginine
methyl ester (L-NAME, 30 lg in 5 lL), a NOS inhibitor,
or artificial cerebrospinal fluid (aCSF) was administered
intrathecally 1 h before the behavior testing at 10 wk of
age. The animals were given the second dose the next
day, followed by perfusion and tissue collection 1 h after
the second administration. The dose of the inhibitors
used was based on published data [MK801 (Mao et al.,
1992) and L-NAME (Meller et al., 1994; Zajac et al.,
2000)]. None of the drug treatments caused significant
motor impairment or distress to the animals.
Minipump Placement
An osmotic minipump (Alzet minipump model 1007D,
100 lL volume with a 0.51 lL/h infusion rate; Duent
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Corporation, Cupertino, CA) was used for continuous in-
trathecal infusion into the LSC region. The minipumps
were filled with aCSF with 10% dimethyl sulfoxide with
or without mitogen-activated protein kinase (MAPK)
(MEK) 1/2 inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis(o-
aminophenylmercapto) butadiene (UO126, 1 lg/lL; Cal-
biochem, La Jolla, CA), or aCSF (Obata et al., 2007).
The minipumps were implanted into the dorsal subcu-
taneous space between the shoulder blades of each
mouse at 7 wk of age under sterile conditions. A cau-
Fig. 1. Increased peripheral SP input and astrocytosis in the LSC of
db/db mice. A: SP immunoreactivity was detected in lamina I (arrow-
heads) in db1 mice. D: SP immunoreactivity extended into lamina II
(arrowheads) and lamina III (asterisks) in db/db mice. B,E: GFAP-posi-
tive astrocytes were detected in lamina I–III in the LSCDH of db/db
mice (compare B to E, arrows). C,F: Merged images demonstrated the
enhanced astrocyte aggregation to SP-positive fibers in db/db mice. Bar
5 50 lm. N 5 4.
Fig. 2. Increased pERK1/2-positive neurons in the LSCDH of db/
db mice. A–C: SP (A) and pERK1/2 (B) immunohistochemistry in
db1 mice. Minimal pERK1/2-positive neurons were detected in db1
mice (B, arrow). D–F: SP (D) and pERK1/2 (E) immunohistochemis-
try in db/db mice. In comparison to db1 mice, an increase in pERK1/
2-positive neurons was observed in lamina I–III of db/db mice (E,
arrows). Bar 5 20 lm. N 5 4.
1303SPINAL MECHANISMS FOR DIABETIC PAIN
GLIA
dally directed polyethylene cannula (Becton Dickinson
and Company, Sparks, MD) was threaded subcuta-
neously and inserted into the subarachnoid space
at the L5 level. The intrathecal infusion lasted for 1
wk at which time the mice reached 8 wk of age
(Cheng et al., 2010).
Data Presentation and Statistical Analyses
All data are presented as group means 6 SEM. The
data between db1 and db/db mice of the same age
were analyzed using the Mann–Whitney test. Statisti-
cal comparisons between different age groups were
made by one-way analysis of variance tests followed
by a post hoc Tukey’s multiple comparison test. A P
value of less than 0.05 was considered statistically sig-
nificant.
RESULTS
Enhanced Presynaptic SP Inputs and
Astrocytosis in the Superficial Lamina of the
SCDH in db/db Mice
We previously determined that db/db mice develop me-
chanical allodynia from 6 to 12 wk of age (Cheng et al.,
2009). In this study, we hypothesized that increased SP
release from presynaptic terminals triggers the neuron–
glial interactions in the SCDH of db/db mice to maintain
chronic PDN. We studied SP IHC in SC from db1 and db/
db mice at 10 wk of age. In addition, we also performed
IHC for GFAP to monitor the associated astrocytosis in
LSCDH. In db1 mice, SP expression is mostly in presyn-
aptic terminals of lamina I (Fig. 1A, arrowheads). In db/
db mice, there is more extensive SP immunoreactivity in
lamina I and II (Fig. 1D, arrowheads) and lamina III
(Fig. 1D, asterisks). In addition, increased numbers of
Fig. 3. Increased phosphorylation of NR1 and ERK1/2, but not JNK
in the LSC of db/db mice. A: Representative immunoblots for pNR1 and
total NR1. Increased NR1 phosphorylation was detected from 8 to 16
wk of age, with maximal pNR1 levels detected at 10 wk of age. B: Den-
sitometric analysis of NR1 phosphorylation. A 2.5-fold increase in NR1
phosphorylation was detected at 10 wk of age. C: Representative immu-
noblots for pERK1/2 and total ERK1/2. Increased ERK1/2 phosphoryla-
tion was detected from 8 to 16 wk of age with maximum pERK1/2 lev-
els detected at 10 wk of age. D: Densitometric analysis of ERK1/2 phos-
phorylation. A threefold increase in ERK1/2 phosphorylation was
detected at 10 wk of age. E: Representative immunoblots for pJNK and
total JNK. F: Densitometric analysis of JNK phosphorylation. No sig-
nificant change of JNK phosphorylation was detected in db/db mice. *P
< 0.05; **P < 0.01. N 5 4.
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GFAP-positive astrocytes were detected in lamina I–III in
db/db mice (compare Fig. 1B to Fig. 1E, arrows). These
astrocytes were larger and with long processes, indicating
they were activated astrocytes (Fig. 1E, arrows).
Increased pERK1/2-Positive Neurons in
Superficial Lamina of SCDH in db/db Mice
To demonstrate the activation of postsynaptic SCDH
neurons at the same stage, we performed double IHC for
SP and pERK1/2 using LSC sections from 10-wk-old
mice (Fig. 2). SP IHC demonstrated presynaptic nocicep-
tive fibers in SCDH (Fig. 2A,D). Only minimal levels of
pERK1/2 expressed in the LSCDH of db1 mice was
observed (Fig. 2B, arrow). In contrast, intense pERK1/2
immunoreactivity was detected in neurons of lamina I–
III in db/db mice (Fig. 2E,F, arrows).
Phosphorylation of Nr1 and Erk1/2 During
the Period of Mechanical Allodynia
We hypothesized that NMDAR signaling is the key
mechanism for the neuron–glial activation in SCDH. To
Fig. 4. Upregulation of nNOS expression in db/db mice. A: Represen-
tative nNOS immunoblots used proteins from the LSC of db1 and db/db
mice. Increased nNOS expression was detected in db/db mice at 10 wk of
age. B: Densitometric analysis of nNOS immunoblots. There was a 1.8-
fold increase of nNOS expression in db/db mice compared with db1 mice
at 10 wk of age. C–K: Increased nNOS immunoreactivity was detected
in neurons and astrocytes in db/db mice. C–E: Few nNOS-positive neu-
rons were detected in lamina II (arrows) and III (arrowheads) in db1
mice. F–H: Increased numbers of nNOS-positive neurons were detected
in laminas II (arrows) and III (arrowheads) of LSCDH of db/db mice. In
addition, glial cell processes (G, asterisks) were observed to be nNOS pos-
itive. I–K: High-power confocal images identified nNOS-positive astro-
cytes. The nNOS-positive glial cells (J, arrows) expressed GFAP (I,
arrows) and were identified as astrocytes (K, arrows). **P < 0.01. N 5 4.
C–H, Bar 5 20 lm; I–K, Bar 5 5 lm.
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test our hypothesis, we first studied the activation
of NMDAR during the period of mechanical allodynia in
db/db mice. N-methyl-D-aspartate (NMDA) activation is
determined using immunoblots of pNR1. As demonstrated
in Fig. 3A, enhanced NR1 phosphorylation was detected
at 8 and 10 wk of age in db/db mice compared with db1
mice of the same age. The total NR1 signals on the same
immunoblots demonstrated unchanged total NR1 protein
levels, and actin signals were used as corresponding load-
ing controls. Densitometric studies determined that there
were enhanced pNR1 levels at 8–12 wk of age with the
maximal NR1 phosphorylation detected at 10 wk of age
with a 2.5-fold increase over the control db1 mice
(Fig. 3B). NR1 phosphorylation was not detected before
diabetes (at 5 wk). Although its levels were reduced, the
pNR1 signal remained above the control level after the
period of mechanical allodynia (at 16 wk). The levels of
ERK1/2 phosphorylation were determined by pERK1/2
immunoblots (Fig. 3C). In accordance with NR1 phospho-
rylation, enhanced pERK1/2 levels in SC were detected at
8–16 wk of age, with maximal levels of phosphorylation
detected at 10 wk of age (Fig. 3C). ERK1/2 immunoblots
demonstrated unchanged total protein expression, and
actin immunoblots served as loading controls. Densito-
metric analysis demonstrated that enhanced pERK1/2
levels were detected from 8 to 16 wk of age, with a peak at
10 wk of age in db/db mice. Enhanced pERK1/2
levels were not detected at 5 wk of age, before onset of dia-
betes. Nevertheless, significant ERK1/2 phosphorylation
was still detectable at 16 wk of age (Fig. 3D). Unlike NR1
and ERK1/2, there was no change in JNK phosphoryla-
tion in the LSC of db/db mice compared with db1 controls
during the tested periods (Fig. 3E,F).
Increased nNOS Expression in Neurons and
Astrocytes of the SCDH in db/db Mice
Another NMDAR-dependent nociceptive pathway is
nNOS signaling (Freire et al., 2009). As the second step,
we studied nNOS expression during the period of me-
chanical allodynia using immunoblots (Fig. 4A,B). A sig-
Fig. 5. Upregulation of iNOS expression in db/db mice. A: Represen-
tative iNOS immunoblots used proteins from LSC of db1 and db/db
mice. Increased iNOS expression was detected in db/db mice at 10 wk
of age. B: Densitometric analysis of iNOS immunoblots. There was a
3.3-fold increase of iNOS expression in db/db mice compared with db1
at 10 wk of age. C–H: Increased iNOS immunoreactivity was detected
in astrocytes of lamina I–III in db/db mice. C–E: iNOS-positive astro-
cytes were detected in lamina I (C,D, arrows) and their
processes extended into II (C,D, arrowheads) in db1 mice. F–H:
Increased numbers of iNOS-positive astrocytes were detected in lamina
I–III (F–H, arrows) of the LSCDH of db/db mice. **P < 0.01. N 5 4.
Bar 5 20 lm.
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nificant increase of nNOS levels was detected at 10 wk
of age. In parallel, the cell-specific distribution of nNOS
was examined by IHC, demonstrated in Fig. 4C–H.
Increased nNOS immunoreaction was detected in neu-
rons of lamina II and III in SCDH of db/db mice (Fig.
4G,H). Similarly, nNOS was detected in GFAP-positive
astrocytes (Fig. 4I–K).
Increased iNOS Expression in Astrocytes of the
SCDH in db/db Mice
We examined the expression of iNOS during the pe-
riod of mechanical allodynia in the LSCDH of db1 and
db/db mice by immunoblots (Fig. 5A). iNOS expression
was upregulated at 10 wk of age, with a 3.3-fold
increase in db/db mice over that of db1 controls
(Fig. 5A,B). In contrast to nNOS, immunoreactivity of
iNOS was detected only in astrocytes and not in neurons
on lamina I–III of the SCDH (Fig. 5C–H).
Effects of MK801, UO126, and L-NAME Treatments
on Mechanical Allodynia in db/db Mice
To determine whether NR1, ERK1/2, nNOS, and
iNOS are important for the development of mechanical
allodynia at 10 wk of age, we treated db/db mice and
control mice with inhibitors for each pathway. First,
MK801, a NMDAR inhibitor, was administered to both
db1 and db/db mice at 10 wk of age. MK801 treat-
ment significantly reduced the degree of decreased me-
chanical thresholds in db/db mice, reversing mechani-
cal allodynia in db/db mice (Fig. 6A). Second, UO126,
a MAPK inhibitor, was administered intrathecally for
7 d to both db1 and db/db mice at 9 wk of age by
using implanted minipumps. Similar to MK801 treat-
ment, UO126 treatment significantly reversed mechan-
ical allodynia in db/db mice (Fig. 6B). Finally, L-
NAME, a nonspecific NOS inhibitor that blocks actions
of both nNOS and iNOS, was injected intrathecally at
10 wk of age. In addition to MK801 and UO126, L-
NAME treatment significantly reduced mechanical allo-
dynia in db/db mice (Fig. 6C).
Effects of MK801 on Enhanced pNR1, pERK,
nNOS, and iNOS Levels in the LSC of db/db Mice
To determine how these signaling events contribute to
the maintenance of mechanical allodynia in db/db mice,
we studied the effects of these three inhibitors on NR1
and ERK1/2 phosphorylation and nNOS and iNOS up-
regulation. First, we tested the effects of MK801. Immu-
noblot analysis demonstrated that MK801 treatment
significantly reduced NR1 (Fig. 7A,B) and ERK1/2 phos-
phorylation (Fig. 7C,D). In addition, MK801 treatment
inhibited the upregulation of nNOS (Fig. 7E,F) and
iNOS (Fig. 7G,H) expression in db/db mice. In contrast,
MK801 treatment did not affect pERK1/2 and NOS lev-
els in db1 mice.
Furthermore, MK801 treatment significantly reduced
the number of pERK1/2- and nNOS-positive
neurons in the LSCDH of db/db mice (Fig. 8). Consist-
ent with Figs. 3 and 4, pERK1/2 and nNOS were
detected in neurons in the corresponding lamina of the
LSCDH in db/db mice (Fig. 8B,C). Although MK801
treatment did not affect the SP immunoreactivity in
db/db mice (Fig. 8A,D), it significantly reduced the
number of pERK1/2-positive (Fig. 8B,E) and nNOS-pos-
itive (Fig. 8C,F) neurons in LSCDH of db/db mice.
Quantitative analyses revealed significant reductions of
pERK1/2-positive (Fig. 8G) and nNOS-positive (Fig.
8H) neurons after MK801 treatment in the LSCDH of
db/db mice.
Fig. 6. MK801, UO126, and L-NAME inhibit mechanical allodynia
in db/db mice. A: MK801 treatment significantly reversed decreased
mechanical thresholds in db/db mice to control levels. B: UO126 treat-
ment significantly reversed decreased mechanical thresholds in db/db
mice to the levels of control db1 mice. C: L-NAME treatment signifi-
cantly reversed decreased mechanical thresholds in db/db mice to the
control levels. **P < 0.01. N 5 4.
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Effects of MK801 on Astrocytosis in the LSC
of db/db Mice
In addition to inhibition of neuronal activity, MK801
treatment reduced astrocytosis in the LSCDH of db/db
mice (Fig. 9). GFAP immunoblot analysis detected a
threefold increase of GFAP expression in the LSC of
control-treated db/db mice in comparison with db1
mice of the same condition (Fig. 9A,B). MK801 treat-
ment significantly reduced the GFAP levels of db/db
mice to the db1 levels (Fig. 9A,B). In parallel, GFAP
IHC also demonstrated reduced numbers of astrocytes
in the LSCDH of db/db after MK801 treatment
(Fig. 9E,F).
Fig. 7. MK801 inhibits NR1 and ERK1/2 phosphorylation and
nNOS and iNOS upregulation in db/db mice. A: Representative immu-
noblots of pNR1, total NR1, and actin from the LSC of db1 and db/db
mice treated with control solution (C) or MK801. MK801 treatment
decreased NR1 phosphorylation in db/db LSC and had no effect on db1
mice. B: Densitometric analysis of pNR1 immunoblots. MK801 treat-
ment decreased levels of NR1 phosphorylation back to control levels. C:
Representative immunoblots of pERK1/2, total ERK1/2, and actin from
LSC of db1 and db/db mice treated with control solution (C) or
MK801. MK801 treatment decreased ERK1/2 phosphorylation in db/db
but not in db1 mice. D: Densitometric analysis of pERK1/2 immuno-
blots. MK801 treatment decreased the levels of ERK1/2 phosphoryla-
tion back to control levels. E: nNOS immunoblots revealed that MK801
treatment reduced nNOS upregulation in db/db mice. F: Densitometric
analysis of nNOS immunoblots demonstrated that MK801 treatment
decreased nNOS levels in db/db mice back to control levels. G: iNOS
immunoblots showed that MK801 treatment reduced iNOS upregula-
tion in db/db mice. H: Densitometric analysis of iNOS immunoblots
demonstrated that MK801 treatment decreased iNOS levels in db/db
mice back to control levels. *P < 0.05; **P < 0.01. N 5 4.
1308 DAUCH ET AL.
GLIA
Effects of UO126 on Enhanced pERK, nNOS, and
iNOS Levels in the LSC of db/db Mice
As expected, intrathecal UO126 treatment signifi-
cantly inhibited ERK1/2 phosphorylation in db/db mice
(Fig. 10A,B). However, UO126 treatment had no effect
on increased levels of nNOS (Fig. 10C,D) and iNOS (Fig.
10E,F) in db/db mice. In addition, UO126 treatment had
no significant effects on pERK1/2, nNOS, or iNOS levels
in db1 mice.
Effects of L-NAME on Enhanced pNR1, pERK,
nNOS, and iNOS Levels in LSC of db/db Mice
Similar to MK801, L-NAME treatment significantly
reduced NR1 (Fig. 11A,B) and ERK1/2 phosphorylation
(Fig. 11C,D) in db/db mice. L-NAME treatment had no
effects on control levels of pNR1 and pERK1/2 in db1
mice. In addition, L-NAME treatment reduced levels of
nNOS (Fig. 11E,F) and iNOS (Fig. 11G,H) in db/db mice,
but not in db1 mice.
DISCUSSION
PDN is a prevalent cause of chronic neuropathic pain
in patients with type 2 diabetes. In our current report,
we study the involvement of spinal neuron–astrocyte
signaling for enhanced nociception in PDN of type 2 dia-
betes. Our current findings suggest that increased pe-
ripheral nociceptive input is essential for the subsequent
development of SC mechanisms for mechanical allodynia
(Cheng et al., 2009). This notion is supported by Latre-
moliere and Woolf (2009), who reviewed the literature
and recognized that increased levels of subthreshold
synaptic inputs to SCDH nociceptive neurons could
induce central neural plasticity.
Our results indicate that ERK1/2 phosphorylation
occurred in neurons in lamina I–III of the LSC during
the maintenance phase of mechanical allodynia in db/db
mice. These results are consistent with published data
from models of inflammatory pain (Cheng et al., 2008;
Gao and Ji, 2010a) and pain from electric stimulation
(Lever et al., 2003), capsaicin treatment (Ji et al., 1999),
and nerve injuries (Obata et al., 2004). Our data suggest
Fig. 8. MK801 treatment significantly reduces the number of
pERK1/2- and nNOS-positive neurons in the LSCDH of db/db mice.
A,D: MK801 treatment had no effect on SP expression in the LSCDH
of db/db mice. B,E: MK801 treatment reduced the number of pERK1/2-
positive neurons in the LSCDH of db/db mice. C,F: MK801 treatment
reduced the number of nNOS-positive neurons in the LSCDH of db/db
mice. G: MK801 treatment reduced the number of pERK1/2-positive
neurons in the LSCDH in db/db mice back to control levels. H: MK801
treatment reduced the number of nNOS-positive neurons in the
LSCDH in db/db mice back to control levels. *P < 0.05; **P < 0.01. N
5 4. Bar 5 20 lm.
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that increased ERK phosphorylation is associated with
increased presynaptic SP secretion. In support of our hy-
pothesis, Ji et al. (2002) reported that NK1, the SP recep-
tor, is colocalized with activated ERK in painful condi-
tions. In addition, Kawasaki et al. (2004) directly applied
SP to SC, which in turn induced spinal ERK activation.
In the current report, we discovered increased astrocy-
tosis in the LSCDH, suggesting increased neuronal–
astrocyte interaction during the maintenance phase of
mechanical allodynia in db/db mice. Comparable to our
data, Liao et al. (2011) reported astrocyte activation in
LSCDH of db/db mice at the same age. In addition,
astrocyte activation has been reviewed in various animal
models for both inflammatory and neuropathic pain
(Gao and Ji, 2010b). In contrast to astrocyte activation,
we failed to detect microglial activation using either
OX42 or Iba1 IHC (data not shown) consistent with the
findings of Liao et al. (2011) that minocycline did not
affect the mechanical allodynia in db/db mice.
NMDAR activation is a well-known mechanism to
mediate central sensitization for prolonged and
enhanced nociception in animal models of inflammatory
and neuropathic pain (Woolf, 2007). However, evidence
of spinal NMDAR activation in PDN of type 2 diabetes
is still lacking. On the basis of a plethora of published
evidence in other pain models (Mao et al., 1992; Persson
et al., 1995; Ren et al., 1992), we studied the roles of
NMDAR and its downstream signaling pathways for the
maintenance of mechanical allodynia in the db/db
mouse, an animal model of type 2 diabetes. In addition
Fig. 9. MK801 inhibits GFAP expression and astrocytosis in db/db
mice. A: GFAP immunoblots used protein samples from the LSC of db1
and db/db mice treated with control or MK801. Increased amount of
GFAP protein was detected in control-treated db/db mice. The GFAP
upregulation in db/db mice was inhibited by MK801 treatment. B: Den-
sitometric analysis of GFAP immunoblots demonstrated that MK801
treatment decreased GFAP levels in db/db mice back to that of db1
mice. **P < 0.01. N 5 4. C–F: MK801 treatment reduced the degree of
astrocytosis in db/db mice. Increased number of astrocytes in the
LSCDH in control-treated db/db mice (arrows, compare C and E) was
reduced by MK801 treatment (arrows, compare E and F). Bar 5 20 lm,
N 5 4.
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to the current study, Liao et al. (2011) reported a similar
time course of NR1 phosphorylation in the db/db mouse
model. A majority of other published studies for spinal
mechanisms in PDN have been performed in models of
type 1 diabetes. Daulhac et al. (2006) reported that
there are NMDAR-dependent activation of MAPKs,
including ERK1/2, p38, and JNK, in the LSC at 21 days
after induction of type 1 diabetes by streptozotocin (STZ)
treatment. In addition, Rondon et al. (2010) detected
NR1 phosphorylation in the LSC in the STZ rat model 4
wk after diabetes. In their report, magnesium sulfate
treatment, which served as an inhibitor for NMDAR,
not only suppressed NR1 phosphorylation but also
decreased pain behaviors in diabetic animals. These
reports indicate that NMDAR activation could be a
mechanism for PDN in both type 1 and type 2 diabetes.
Our current results demonstrated upregulation of
nNOS in the SCDH. We observed nNOS expression in
neurons and astrocytes of lamina II and III. These
results are consistent with a previous report by Rusche-
weyh et al. (2006). In their report, nNOS-positive neu-
rons are mostly interneurons, similar to our current
findings. Interestingly, neurons that contain soluble gua-
nylyl cyclase, the target molecule of NO, are distributed
mostly in lamina I and II. They concluded that NO dif-
fused from the nNOS-positive interneurons to act on
projection neurons in lamina I. On the basis of immuno-
histochemical distribution of nNOS in db/db mice, we
speculate that similar mechanisms might be involved in
PDN of type 2 diabetes. However, these mechanisms
might not be associated with PDN of type 1 diabetes.
For example, Vareniuk et al. (2009) detected reduced
thermal hyperalgesia, but not mechanical allodynia in
STZ-treated nNOS knockout mice compared with dia-
betic wild-type mice. Unfortunately, iNOS expression
was not studied in their report. In addition, Bujalska et
al. (2008) reported that iNOS, but not nNOS, is involved
in PDN of STZ rats by using specific NOS inhibitors. In
our current report, we detected increased expression of
both nNOS and iNOS in db/db mice. To block both NOS
Fig. 10. UO126 has no effect on nNOS and iNOS expression. A:
Representative immunoblots of pERK1/2, total ERK1/2, and actin from
the LSC of db1 and db/db mice intrathecally treated with control aCSF
(C) or aCSF with UO126. UO126 treatment decreased ERK1/2 phospho-
rylation in db/db but not in db1 mice. B: Densitometric analysis of
pERK1/2 immunoblots. UO126 treatment decreased the levels of ERK1/
2 phosphorylation back to control levels. C: Representative immuno-
blots of nNOS, iNOS, and actin from the LSC of db1 and db/db mice
treated with control solution (C) or UO126. UO126 treatment had no
effect on nNOS and iNOS levels in db/db mice. D,E: Densitometric
analysis revealed that UO126 treatment did not affect nNOS and iNOS
levels in db/db mice. *P < 0.05; **P < 0.01. N 5 4.
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isoforms, we used L-NAME, a nonspecific NOS inhibitor.
We acknowledge that L-NAME treatment only provides
information for general NOS-mediated actions. Further
studies using specific NOS inhibitors are necessary to
elucidate whether nNOS and/or iNOS mediate PDN in
type 2 diabetes.
In the current report, we detected expression of iNOS
in astrocytes of lamina I. Similar to our findings, iNOS
expression is reported in a variety of pain models for
both inflammatory and neuropathic pain (Freire et al.,
2009). In the SCDH, astrocyte-derived iNOS was impli-
cated in presynaptic potentiation, a form of long-term
Fig. 11. L-NAME inhibits NR1 and ERK1/2 phosphorylation and
nNOS and iNOS upregulation in db/db mice. A: Representative immu-
noblots of pNR1, total NR1, and actin from the LSC of db1 and db/db
mice intrathecally treated with control aCSF (C) or aCSF with L-
NAME. L-NAME treatment decreased NR1 phosphorylation in db/db
but not in db1 mice. B: Densitometric analysis of pNR1 immunoblots.
L-NAME treatment decreased the levels of NR1 phosphorylation back
to that of control db1 mice. C: Representative immunoblots of pERK1/
2, ERK1/2, and actin from the LSC of db1 and db/db mice treated with
control solution (C) or L-NAME. L-NAME treatment decreased ERK1/2
phosphorylation in db/db but not in db1 mice. D: Densitometric analy-
sis of pERK1/2 immunoblots. L-NAME treatment decreased the levels
of ERK1/2 phosphorylation back to control levels. E: nNOS immuno-
blots revealed that L-NAME treatment reduced nNOS upregulation in
db/db mice. F: Densitometric analysis of nNOS immunoblots demon-
strated that L-NAME treatment decreased nNOS levels in db/db mice
back to control levels. G: iNOS immunoblots showed that L-NAME
treatment reduced iNOS upregulation in db/db mice. H: Densitometric
analysis of iNOS immunoblots demonstrated that L-NAME treatment
decreased iNOS levels in db/db mice back to control levels. **P < 0.01;
***P < 0.001. N 5 4.
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potentiation, to enhance nociception (Amitai, 2010). The
current findings suggest that a similar phenomenon
could exist in the SCDH of db/db mice to mediate me-
chanical allodynia.
Our findings indicate that ERK1/2 phosphorylation is
a NMDAR-dependent event. Several studies have shown
that glutamate transmission through NMDARs is essen-
tial for ERK activation in SCDH neurons (Ji et al., 1999;
Lever et al., 2003). Analogous to our findings, Daulhac
et al. (2006) reported not only ERK1/2 but also p38 and
JNK activation in STZ-treated rats. Conversely, we
failed to detect the activation of JNK and p38 (data not
shown) in the LSC of db/db mice. In addition, we did not
detect pERK1/2 immunoreactivity in microglia as
reported in the study by Daulhac et al. (2006). This dis-
crepancy could reflect a distinction in the SC mecha-
nisms that mediate PDN in type 1 and type 2 diabetes
or a species-specific difference between these studies. We
are currently investigating NMDAR and MAPK activa-
tion in PDN of STZ-treated db1 mice to better under-
stand the cause of these discordant observations.
In accord with other studies, our data demonstrated
that ERK1/2 phosphorylation is mostly located in the su-
perficial layers (lamina I–III) of the SCDH (Ji et al.,
2009). We speculate that these pERK1/2-positive neu-
rons are projection neurons that provide the spino-
thalamic tract. In agreement with our hypothesis, Slack
et al. (2005) identified the activation of ERK1/2 in the
Trk B-positive SCDH projection neurons that provide
the spinothalamic tract after brain-derived neurotrophic
factor treatment. The current findings that demon-
strated UO126 inhibition of mechanical allodynia with-
out affecting the increased nNOS and iNOS levels sug-
gest that pERK1/2-positive neurons are likely the projec-
Model 1: Working hypothesis of neuron-astrocyte interactions during
the maintenance phase of mechanical allodynia in db/db mice. During
the later period of mechanical allodynia, enhanced presynaptic SP and
glutamate (Glu) release induces postsynaptic NR1/ERK1/2 phosphoryla-
tion in projection neurons. In addition, NR1 signaling increases nNOS
expression in interneurons and both nNOS and iNOS upregulation in
astrocytes in the LSCDH. These regulatory mechanisms trigger NO
production, which in turn further enhances NR1 signaling in projection
neurons.
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tion neurons that integrate the actions of NO from
neighboring interneurons and astrocytes in the SCDH
and transmit nociceptive signals to the higher levels of
the central nervous system.
Our data suggested MK801 treatment inhibited both
nNOS and iNOS expression. Unfortunately, little has
been published about NMDAR-mediated NOS expression
aside from our current report. In the enteric nervous
system, MK801 treatment inhibited the upregulation of
nNOS in the enteric plexus after ischemia–reperfusion
(Calcina et al., 2005). In addition, MK801 treatment
reduced increased SC nNOS levels in morphine toler-
ance (Wong et al., 2000). After traumatic SC injury,
MK801 treatment reduced inflammatory reactions,
including enhanced iNOS expression and improved func-
tion recovery (Esposito et al., 2011). A similar phenom-
enon was also observed after hypoxic brain injury
(Jander et al., 2000). Our results suggest that similar
NMDAR-mediated NOS expression is involved in inter-
neurons for the mediation of PDN of type 2 diabetes.
Specifically, this signaling event occurs in interneurons
of lamina II and III and is ERK-independent.
Our data indicated that MK801 inhibited the
enhanced astrocytosis in SCDH of db/db mice. These
findings suggest that NMDAR signaling mediates local
astrocyte activation. In the literature, several NMDAR-
dependent factors, such as chemokines, and cytokines,
are reported to mediate enhanced astrocytosis in a cen-
tral pain model after spinal cord injury (Gwak et al.,
2012). Our studies provide evidence that similar mecha-
nisms could be associated with PDN in type 2 diabetes.
Our results from L-NAME treatment suggest that NO
is essential for the maintenance of mechanical allodynia
in db/db mice. In support of our findings, spinal NO was
reported to mediate NMDA-induced hyperalgesia in
other pain models. For example, Kitto et al. (1992)
observed inhibition of NMDA-induced hyperalgesia as a
result of intrathecal L-NAME treatment. Increased NOS
expression was also reported in an inflammatory pain
model (Infante et al., 2007). In addition, L-NAME inhibits
neuropathy-induced thermal hyperalgesia (Inoue et al.,
1998; Thomas et al., 1996).
Our data suggest that NO mediates increased NR1
and ERK1/2 phosphorylation. Because pERK1/2 is
mostly located in the projection neurons of lamina I–III,
distinct from nNOS-positive interneurons, these results
indicate that there is NO-mediated NMDAR activation
in projection neurons. In support of our hypothesis,
Malmberg and Yaksh (1993) reported that intrathecal L-
NAME treatment blocked the second phase of pain from
the formalin test and NMDA-induced thermal hyperal-
gesia, suggesting NO enhances NMDAR actions. In
addition, Sorkin (1993) reported that L-NAME treat-
ment directly inhibits increased levels of glutamate and
citrulline, an amino acid co-product of NO synthesis, in
response to spinal administration of NMDA. Other than
indirectly enhancing pERK1/2 levels through increased
NMDAR activation, NO could also trigger ERK1/2 phos-
phorylation by mechanisms independent of NMDAR sig-
naling. Komatsu et al. (2009) reported that NO mediates
morphine-3-glucuronide-induced pain through the NO-
cGMP-PKG pathway. Because MK801 completely blocks
increased pERK1/2 levels in our current study, NO-de-
pendent ERK1/2 activation is less likely to occur in our
model. Similar to NO, interleukin (IL)-1b also contrib-
utes to enhanced NMDAR phosphorylation in db/db
mice, suggesting that multiple factors are involved in
this action (Liao et al., 2011). Both NO and IL-1b–medi-
ated NMDAR phosphorylation is likely triggered by re-
active oxygen species generated from type 2 diabetes
(Liao et al., 2011).
In addition to increased nNOS and iNOS expression
in the SCDH, we detected evidence that there is
NMDAR-mediated ERK1/2 activation during the main-
tenance phase of mechanical allodynia in db/db mice.
Our data suggest that increased NMDAR-pERK1/2 sig-
naling in projection neurons is an essential step for
the maintenance of mechanical allodynia in db/db
mice. In addition, increased NOS expression in nearby
interneurons and astrocytes further serves as a posi-
tive feedback mechanism to enhance NMDAR activa-
tion by NO (Model 1). This model is different from the
one proposed by Liao et al., who suggested a one-way
mechanism where astrocyte-derived IL-1b induces neu-
ronal NMDAR activation and mechanical allodynia. In
contrast, our model suggests a more complicated neu-
ron–astrocyte network to mediate PDN in type 2
diabetes.
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